Patient Focus

Patient Focus
Rare Disease Day 2016: The Patient Voice

Alone we are rare. Together we are strong.

See All

Blog

The “Intimacy” of Working in Rare Diseases
In one of my earliest interactions with a rare disease group, the mother of a child suffering from a  rare skin disorder described an incident...
See All
  1. Opportunities

    Opportunities

    We scour scientific literature, visit universities and attend medical conferences to identify potential compelling therapies.

  2. Screen/Diligence

    Screen/Diligence

    Our rapid assessment with internal and external resources determines the path forward for this new clinical candidate.

  3. De-risking

    De-risking

    An IND-ready asset is ready for Series A funding with a NewCo to bring this orphan drug candidate to patients.

  4. Launch

    Launch

    Cydan NewCos have an investible corporate story, access to capital, experienced management and a
    clear path forward.

View Our Collaborative Model

  • Vtesse Logo

    Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved.

    Learn More
  • imara newco logo

The Cydan Model

Our Rare Disease Drug Development Model Cydan is focused on accelerating meaningful therapies for people with rare monogenic, non-oncologic diseases. We start with a compelling scientific idea or promising drug candidate from collaborators in academia and/or industry, and then efficiently advance the therapy through pre-clinical research to enable the establishment of an independent company to progress drug candidates through clinical and regulatory development to commercialization.

View Our Collaborative Model

Cydan NewCos

Cydan is focused on accelerating the development of meaningful therapies for people with rare genetic diseases, excluding oncology. Our goal is launching an independent company to drive the drug candidate through clinical and regulatory development to commercialization.

Learn More